Ecallantide Dyax/Genzyme

Current Opinion in Investigational Drugs

Volumn 7, Issue 3, 2006, Pages 282-290

  Lehmann, Andreas ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; APROTININ; COMPLEMENT COMPONENT C1S INHIBITOR; DX 88; ECALLANTIDE; ICATIBANT; KALLIKREIN; KALLIKREIN INHIBITOR; PLACEBO; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTICOAGULATION; BLOOD CLOTTING TIME; BRAIN ISCHEMIA; CLINICAL TRIAL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; HEART SURGERY; HUMAN; NEUROPROTECTION; NONHUMAN; POSTOPERATIVE HEMORRHAGE; PROTEIN SYNTHESIS INHIBITION; REVIEW; SEPSIS; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING;

ANALGESICS, NON-NARCOTIC; ANGIONEUROTIC EDEMA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS, PHASE III; HUMANS; KALLIKREINS; PEPTIDES; RECOMBINANT PROTEINS;

EID: 33644959093     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Dyax Corp - Therapeutics & Imaging. Dyax Corp COMPANY WORLD WIDE WEB SITE 2000 October 27
2. New York State Society of Anesthesiologists 54th Postgraduate Assembly, New York, NY, USA. Gotta AW IDDB MEETING REPORT 2000 December 9-13
3. 2000 Annual Report - Dyax Corporation. Dyax Corp ANNUAL REPORT 2001 March 01
4. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE 3rd J CLIN INVEST 2002 109 8 1057-1063
5. Dyax restructures collaboration with Genzyme. Dyax Corp PRESS RELEASE 2002 June 04
6. Dyax Corp initiates phase I/II trial of DX-88 in patients undergoing cardiopulmonary bypass. Dyax Corp PRESS RELEASE 2002 August 28
7. Dyax launches automated call center to facilitate US enrollment In its phase II trial of DX-88 for hereditary angioedema. Dyax Corp PRESS RELEASE 2002 September 16
8. DX-88, a novel kunitz-type inhibitor of human plasma kallikrein with potential therapeutic use. Mackie IJ, Lawrie AS, Purdie G, Wiliams T, Machin SJ BLOOD 2002 100 11 Pt 2 Abs 3829
9. Dyax presents positive DX-88 data in angioedema patients. Dyax Corp PRESS RELEASE 2003 March 10
10. Genzyme and Dyax announce joint venture for DX-88 in hereditary angioedema. Genzyme General, Dyax Corp PRESS RELEASE 2003 June 24
11. Dyax's DX-88 meets endpoints in heart surgery phase I/II trial. Dyax Corp PRESS RELEASE 2003 December 26
12. Dyax Corp: DX-88 placed on clinical hold based on preclinical dara; review expected soon. Geller M, Holley B, Kassum T, Lian B CIBC WORLD MARKETS CORP 2004 May 25
13. Dyax receives FDA permission to resume DX-88 clinical trials. Dyax Corp PRESS RELEASE 2004 June 04
14. Dyax and Genzyme's angioedema drug is successful in phase II trial. Dyax Corp PRESS RELEASE 2004 June 14
15. Drug Discovery Technology 2004 - IBC's Ninth Annual World Congress (Part II), Advances in Biotherapeutic Discovery, Boston, MA, USA. Zhu Z IDDB MEETING REPORT 2004 August 8-13
16. Dyax and Genzyme's angioedema drug gets Fast Track status. Dyax Corp PRESS RELEASE 2004 October 12
17. Dyax and Genzyme announce final EDEMA1 clinical results at ACAAI meeting; positive DX-88 data for the treatment of hereditary angioedema. Dyax Corp PRESS RELEASE 2004 November 15
18. Individual replacement therapy (IRT) with a pasteurized C1-inhibitor concentrate compared to prophylaxis with danazol in patients with hereditary angioedema (HAE) - a prospective study. Kreuz W, Martinez-Saguer I, Aygoeren-Puersuen E, Rusicke E, Klingebiel T BLOOD 2004 104 11 Abs 1028
19. Dyax and Genxyme's DX-88 shows promise in phase II angioedema trial. Dyax Corp PRESS RELEASE 2005 January 10
20. Dyax Corp reports senior management changes. Dyax Corp PRESS RELEASE 2005 January 20
21. Drug Discovery Technology Europe 2005 - IBC's Ninth Annual Conference and Exhibition, London, UK. Austin S IDDB MEETING REPORT 2005 March 15-17
22. Dyax's angioedema drug safe as subcutaneous dose. Dyax Corp PRESS RELEASE 2005 June 30
23. Clinical trials. Dyax Corp COMPANY WORLD WIDE WEB SITE 2005 July 15
24. Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complex. Bossi F, Fischetti F, Pellis V, Bulla R, Ferrero E, Mollnes TE, Regoli D, Tedesco F J IMMUNOL 2004 173 11 6921-6927
25. Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro. Tanaka KA, Szlam F, Katori N, Vega JD, Levy JH THROMB RES 2004 113 5 333-339
26. Use of the thrombelastograph to assess the in-vitro effects of DX-88, a novel kallikrein inhibitor, in cardiopulmonary bypass. Self R, Mackie I, Jenkins A, Sanders J, Williams A, Machin S, Mythen M BR J ANAESTH 2004 932 318P
27. Neuroprotective effect of plasma kallikrein inhibitor DX-88 on brain ischemia/reperfusion brain injury. Bergamaschini L, Rossi E, Storini C, De Simoni MG MOL IMMUNOL 2004 41 2-3 208
28. DX-88 a recombinant inhibitor of human plasma kallikrein. Evaluation of efficacy and safety in patients with hereditary angioedema. Williams I, Cicardi M, Bork K, Gonzalez-Quevedo T, Caballero T J ALLERGY CLIN IMMUNOL 2003 111 4 908
29. Assessment of a single controlled ventilation inhalation exposure to a therapeutic peptide in cynomolgus monkeys. Sparrow B, Baird L, Koester A, Moutvic R, Beihn R, Gumbhir SK, Brooker M, Grossi I TOXICOL SCI 2003 72 1 Suppl 294
30. DX-88 and HAE: A developmental perspective. Williams A, Baird LG TRANSFUS APHERESIS SCI 2003 29 3 255-258
31. DX-88 a recombinant inhibitor of human plasma kallikrein. Efficacy and safety in hereditary and acquired angioedema. Cicardi M, Gonzalez QT, Caballero T, Bork K, Williams A MOL IMMUNOL 2003 40 2-4 197-198
32. A novel r-polypeptide, Kunitz-type inhibitor with high specificity for plasma kallikrein and potential for therapeutic use. Mackie IJ, Lawrie AS, Wilbourn B, Purdy G, Jenkins A, Williams A, Machin SJ BR J HAEMATOL 2003 121 Suppl 1 42
33. In vitro effects of DX-88, a novel inhibitor of kallikrein and contact activation. Tanaka KA, Sato N, Szlam F, Katori N, Levy JH ANESTH ANALG 2003 964 Suppl SCA 15
34. Whole blood thromboelastography and platelet function studies with DX-88, a Kunitz-type inhibitor of kallikrein. Wilbourn BR, Mackie IJ, Jenkins AH, Williams A, Machin SJ J THROMB HAEMOST 2003 1 P1101
35. A novel r-polypeptide, kunitz-type inhibitor with high specificity for plasma kallikrein and potential for therapeutic use. Mackie I, Purdy G, Lawrie AS, Williams A, Machin SJ J THROMB HAEMOST 2003 1 7 Suppl OC126
36. Dyax Corp announces third quarter financial results; HAE program on track to begin phase III trial before year end; R&D pipeline advances in oncology. Dyax Corp PRESS RELEASE 2005 October 26
37. Dyax announces positive final results from phase I trial of subcutaneous DX-88; positive experience with subcutaneously administered DX-88 in the ongoing, phase II open-label EDEMA2 trial for hereditary angioedema. Dyax Corp PRESS RELEASE 2005 Nov 07
38. Dyax and Genzyme initiate pivotal phase III trial of subcutaneously administered DX-88 for the treatment of hereditary angioedema. Dyax Corp PRESS RELEASE 2005 December 08
39. Plasma kallikrein inhibitor DX-88 protects against brain ischemia/reperfusion injury. Rossi E, Storini C, Maiocchi D, De Simoni MG, Bergamaschini L J CEREB BLOOD FLOW METAB 2005 25 S46
40. Activated thrombelastograph reaction (r) time is contact factor dependent and prolonged by DX-88, a novel kallikrein inhibitor in cardiopulmonary bypass. Self RE, Mackie IJ, Wlliams AH, Jenkins A, Mythen MG ANESTHESIOLOGY 2004 101 A270
41. Long-term treatment of hereditary angioedema with attenuated androgens: A survey of a 13-year experience. Cicardi M, Bergamaschini L, Cugno M, Hack E, Agostoni G, Agostoni A J ALLERGY CLIN IMMUNOL 1991 87 4 768-773
42. Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. Mojcik CF, Levy JH ANN THORAC SURG 2001 71 2 745-754
43. Hereditary angioedema: A broad review for clinicians. Nzeako UC, Frigas E, Tremaine WJ ARCH INTERN MED 2001 161 20 2417-2429
44. Current and future therapy for hereditary angioedema. Zuraw BL CLIN IMMUNOL 2005 114 1 10-16
45. Review and application of serine protease inhibition in coronary artery bypass graft surgery. Engles L AM J HEALTH-SYSTEM PHARM 2005 62 18 Suppl 4 9-14
46. Initiating coverage; potential for partnered biologics to treat disorders. Keough P WELLS FARGO SECURITIES LLC 2005 June 30 1-19
47. Aprotinin in perspective. Westaby S ANN THORAC SURG 1993 55 4 1033-1041
48. Review and application of serine protease inhibition in coronary artery bypass graft surgery. Engles L AM J HEALTH-SYST PHARM 2005 62 18 Suppl 49-14
49. Safety and efficacy of methods for reducing perioperative allogeneic transfusion: A critical review of the literature. Wells PS AM J THER 2002 9 5 377-388
50. C1 inhibitor deficiency: Consensus document. Gompels MM, Lock RJ, Abinun M, Bethune CA, Davies G, Grattan C, Fay AC, Longhurst HJ, Morrison L, Price A, Price M, Wetters D CLIN EXP IMMUNOL 2005 139 3 379-394
51. Coagulation disorders of cardiopulmonary bypass. Paprella D, Brister SJ, Buchanan MR INTENSIVE CARE MED 2004 30 10 1873-1881
52. The hemostatic defect of cardiopulmonary bypass. Linden MD J THROMB THROMBOL 2003 163 129-147
53. Examination of the biological safety of a drug derived from mammalian organs. Hubner GE, Koch RC, Sprenger KB, Stadler PJ, Golker CF ARZNEIMITTEL-FORSCH 1996 46 6 657-661
54. The risk associated with aprotinin in cardiac surgery. Mangano DT, Tudor IC, Dietzel C, Multicenter Study of Perioperative Ischemia Research Group, Ischemia Research and Education Foundation N ENGL J MED 2006 354 4 353-356
55. Postoperative cognitive dysfunction after cardiac surgery. Gao L, Taha R, Gauvin D, Othmen LB, Wang Y, Blaise G CHEST 2005 128 5 3664-3670
56. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Bork K, Hardt J, Schicketanz KH, Ressel N ARCH INTERN MED 2003 163 10 1229-1235